ABII » Topics » Capital Requirements

This excerpt taken from the ABII 10-K filed Mar 12, 2010.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

   

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the allocation of cash resources between us and Abraxis Health if the proposed spin-off occurs;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

On April 20, 2009, we announced that our board of directors approved a program to repurchase up to $100 million of the company’s common stock. Share repurchases, if any, will be funded by internal cash resources and will be made through open market purchases. The timing, volume and nature of share repurchases are subject to market prices and conditions, applicable securities laws and other factors, and are at the discretion of management. Share repurchases may be commenced, suspended or discontinued at any time without prior notice.

This excerpt taken from the ABII 10-Q filed May 8, 2009.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the allocation of cash resources between us and Abraxis Health if the proposed spin-off occurs;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe our cash and cash equivalents on hand, together with any cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or significant capital projects or significantly reduce our available cash resources in connection with the proposed spin-off of Abraxis Health, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

On April 20, 2009, we announced that our board of directors approved a program to repurchase up to $100 million of the company’s common stock. Share repurchases, if any, will be funded by internal cash resources and will be made through open market purchases. The timing, volume and nature of share repurchases are subject to market prices and conditions, applicable securities laws and other factors, and are at the discretion of management. Share repurchases may be commenced, suspended or discontinued at any time without prior notice.

This excerpt taken from the ABII 10-K filed Mar 6, 2009.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

46


Table of Contents
   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe our cash and cash equivalents on hand, together with any cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or significant capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

This excerpt taken from the ABII 10-Q filed Nov 14, 2008.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe the $700 million contributed to us, together with any cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or significant capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

This excerpt taken from the ABII 10-Q filed Aug 14, 2008.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe the $700 million contributed to us, together with any cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or significant capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

This excerpt taken from the ABII 10-Q filed May 15, 2008.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane® ;

 

   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe the $700 million contributed to us, together with any cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or significant capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

These excerpts taken from the ABII 10-K filed Mar 31, 2008.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

49


Table of Contents
   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe the $700 million contributed to us, together with any cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or significant capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

Capital Requirements


Our future capital requirements will depend on numerous factors, including:

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

expansion of product sales into international markets;

 







 

 

working capital requirements and production, sales, marketing and development costs required to support AbraxaneFACE="Times New Roman" SIZE="1">®;

 


49







Table of Contents








  

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

the need for manufacturing expansion and improvement;

 







  

the requirements of any potential future acquisitions, asset purchases or equity investments; and

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

the amount of cash generated by operations, including potential milestone and license revenue.

STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%">We believe the $700 million contributed to us, together with any cash generated from operations, will be sufficient to finance our operations for at
least the next twelve months. In the event we engage in future acquisitions or significant capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

STYLE="margin-top:18px;margin-bottom:0px">Contractual Obligations

Contractual obligations
represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which we cannot reasonably predict future payment. Accordingly, the table below excludes contractual obligations relating
to milestones and royalty payments due to third parties contingent upon certain future events. Such events could include, but are not limited to, development milestones, regulatory approvals, and product sales. The following information summarizes
our contractual obligations and other commitments as of December 31, 2007:

 






























































































































    Payments due by period

Contractual Obligations

  Total  Less than
1 year
  1-3 years  3-5 years  More than
5 years
   (in thousands)

Purchase obligations and other commitments

  $5,639  $3,677  $412  $400  $1,150

Operating lease obligations

   25,231   6,420   10,004   5,775   3,032
                    

Total

  $30,870  $10,097  $10,416  $6,175  $4,182
                    
This excerpt taken from the ABII 10-Q filed Dec 20, 2007.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

20


Table of Contents
   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe the approximately $700 million contributed to us, together with any cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

This excerpt taken from the ABII 8-K filed Nov 8, 2007.

Capital Requirements

Our future capital requirements will depend on numerous factors, including:

 

   

expansion of product sales into international markets;

 

61


Table of Contents
 

 

working capital requirements and production, sales, marketing and development costs required to support Abraxane®;

 

   

research and development, including clinical trials, spending to develop further product candidates and ongoing studies;

 

   

the need for manufacturing expansion and improvement;

 

   

the requirements of any potential future acquisitions, asset purchases or equity investments; and

 

   

the amount of cash generated by operations, including potential milestone and license revenue.

We believe the approximately $715 million to be contributed to us, together with cash generated from operations, will be sufficient to finance our operations for at least the next twelve months. In the event we engage in future acquisitions or capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki